rheumatoid arthritis
Conditions
Interventions
romosozumab 210mg will be administered subcutaneously every month for one year.
denosumab 60mg will be administered subcutaneously every 6 months for one year.
Sponsors
Tokyo Metropolitan Tama medical center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with rheumatoid arthritis and osteoporosis who are outpatients or hospitalized at participating facilities will be subjected to the current study. Patients with severe osteoporosis according to the diagnostic criteria of the Japan Society of Bone and Metabolism and the Japanese Society of Osteoporosis should be included in the romosozumab group. The control denosumab group includes patients with osteoporosis and rheumatoid arthritis for whom bisphosphonates are not sufficiently effective, or patients with severe osteoporosis who need to increase bone density relatively early.
Exclusion criteria
Exclusion criteria: 1. Patients who are not diagnosed with rheumatoid arthritis or osteoporosis. 2. Patients with a history of ischemic heart disease or cerebrovascular disease within the past 1 year are excluded from the romosozumab group. 3.Patients who are allergic to romosozumab or denosumab. 4.Patients who are judged to be unsuitable as subjects by the principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of bone mineral density at one year after administration of the drugs | — |
Countries
Japan
Contacts
Public ContactYuichi Nagase
Tokyo Metropolitan Tama Medical center Department of Rheumatic surgery
Outcome results
None listed